ICLUSIG PONATINIB 15 AND 45 MG

Strengths available :- 15 mg and 45 mg

 Form :- Tablets

Storage :- Store at controlled room temperature at 20°C to 25°C.

Is the medicine FDA approved :- US FDA Approved

Date of approval :- 14 December, 2012

Dosage :-  Start dosing with 45 mg once daily. Consider reducing the dose of Iclusig for patients with chronic phase (CP) CML and accelerated phase (AP) CML who have achieved a major cytogenetic response.

Common side effects of Iclusig include: arterial thrombosis, venous thrombosis, cardiac failure, congestive heart failure, pleural effusion, bone marrow depression, conjunctival irritation, dizziness, dyspnea, eye pain, fluid retention, gastrointestinal hemorrhage, headache, hyperesthesia, hypertension, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum lipase, paresthesia, peripheral edema, peripheral neuropathy, and xerophthalmia. 

 

Other side effects include: acute myocardial infarction, pancreatitis, severe bone marrow depression, supraventricular tachycardia, blurred vision, coronary artery disease, hemorrhage, hyperuricemia, and tachyarrhythmia.